Investigators tested the utility of ultra-deep genomic testing to predict relapse in patients with myelodysplastic syndrome initiating conditioning therapy for allogeneic hematopoietic cell transplant (alloHCT).
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
Lenalidomide is typically prescribed to individuals with multiple myeloma who have received at least 1 prior therapy.
A CAR-T therapy that targets B-cell maturation antigen showed clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma.
Idecabtagene vicleucel showed clinical benefit and no toxicity concerns in patients with relapsed and/or refractory multiple myeloma.
Most study authors at the 2019 Society of Gynecologic Oncology Annual Meeting failed to disclose industry relationships, a study found.
Age, high-risk disease, renal disease, and active or progressive disease were predictive of worse outcomes for patients with multiple myeloma and COVID-19.
Exposure to doxorubicin during treatment for DLBCL was linked to a higher risk for cardiovascular diseases, highlighting the need for early cardiac surveillance.
The FDA and EMA expressed the need for trial sponsors to coordinate their submissions of initial pediatric study plans and pediatric investigation plans for new oncology drugs.
Most patients with CML are being prescribed costly second-generation TKIs, even though generic imatinib has been available since 2016.
